OM Pharma’s Data Gambit: How Real-World Evidence Transforms a Legacy Drug

GENEVA, Switzerland – June 14, 2026 – This week, as the European Academy of Allergy and Clinical Immunology Congress gets underway, the most significant buzz may not be about a futuristic gene therapy or a novel molecule, but about a therapy with decades of history. Geneva-based OM Pharma is unveiling preliminary results from its REACH study, a colossal real-world evidence (RWE) investigation into its respiratory infection preventative, Broncho-Vaxom®. In a world awash with data, OM Pharma is demonstrating how to turn it into a strategic asset, with profound implications for public health, patient care, and the company's own financial future.

At the heart of the announcement is a dataset of staggering scale: 15,794 patients across China, Italy, and Belgium, whose routine medical records were analyzed to see how they fared on the therapy. The initial findings are compelling, showing significant reductions in the recurrence of respiratory tract infections (RTIs) and a corresponding drop in healthcare visits. For a company with 90 years of expertise in bacterial lysate therapies, this isn't just a product update; it's the validation of a platform and a masterclass in leveraging modern data analytics to unlock new value from an established asset.

The New Gold Standard: Validating Drugs in the Real World

For decades, the randomized controlled trial (RCT) has been the undisputed king of clinical evidence. But its sterile, highly controlled environment often fails to capture the messy reality of medicine. This is where real-world evidence comes in. By analyzing data from everyday clinical practice, RWE provides a crucial understanding of how a treatment performs across diverse populations, comorbidities, and behaviors.

The REACH study—short for Real-World Evidence study of OM-85 in Adults and Children in CHina, Italy, and Belgium—is a landmark in this field. It is not an exaggeration to call it one of the most ambitious RWE studies of its kind. By using secondary data from healthcare databases, OM Pharma has painted a vivid picture of Broncho-Vaxom®'s impact outside the confines of a traditional trial. The preliminary results, indicating a reduction in RTI rates of 28-41% at 12 and 24 months post-treatment, offer the kind of practical validation that resonates with physicians, payers, and patients alike.

This strategic embrace of RWE is exceptionally well-timed. Regulatory bodies, including the European Medicines Agency (EMA), are increasingly looking to RWE to supplement trial data and inform decision-making. The EMA’s recently finalized “Data Quality Framework” signals a clear shift towards integrating real-world data into the regulatory lifecycle. By investing in a study of this magnitude and rigor, OM Pharma is not only reinforcing its product's clinical credentials but is also aligning itself with the future of pharmaceutical validation, building a formidable data-driven moat around its franchise.

A Potent Antidote to a Global Crisis

Beyond the corporate strategy, the REACH study's findings have profound public health implications. Recurrent RTIs are a primary driver of one of the greatest threats to modern medicine: antimicrobial resistance (AMR). Each year, countless patients with coughs and colds receive antibiotic prescriptions, often unnecessarily for viral infections, fueling the rise of drug-resistant superbugs. The societal costs are enormous, measured in strained healthcare systems, lost productivity, and, ultimately, lives.

An effective, non-antibiotic preventive therapy breaks this vicious cycle. By strengthening the body's own immune system to fend off infections, Broncho-Vaxom® reduces the very need for a doctor's visit and the subsequent temptation to prescribe an antibiotic. “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma, in the company’s press release. This reduction is not just a convenience; it's a direct contribution to global antibiotic stewardship.

This aligns perfectly with the 'Vision Zero' theme of the EAACI Congress, which aims for a future free from the burden of allergy and asthma. As respiratory infections are a key trigger for asthma exacerbations, preventing them is a critical piece of the puzzle. By proving its therapy can meaningfully reduce infection rates in the real world, OM Pharma positions itself as a key partner in achieving this ambitious public health goal, transforming its product from a simple therapeutic into a tool for systemic change.

The Bottom-Line Impact of Prevention

For OM Pharma, the business case is just as compelling. The company, which posted robust in-market sales of CHF 350 million in 2025, now holds powerful evidence to drive further market penetration and defend its position. The REACH data provides a potent argument for healthcare payers, who are increasingly focused on value-based care and cost-effectiveness. A therapy that demonstrably reduces doctor visits and prescription costs presents a clear return on investment.

The study also validates the company's core technological platform. Bacterial lysates, which form the basis of Broncho-Vaxom®, have been around for decades. This large-scale, modern validation breathes new life into the platform, de-risking the company's broader pipeline, which includes explorations into new indications and delivery methods, such as an intranasal version of the therapy for allergic asthma. It's a strategic move that leverages a legacy asset to build a foundation for future innovation.

In a competitive landscape that includes vaccines and other immunomodulators, having the largest multi-country RWE study is a significant differentiator. It provides physicians with greater confidence to prescribe the therapy, moving it from a niche option to a mainstream preventive strategy for the millions of patients suffering from the relentless cycle of recurrent infections.

From Clinical Data to Quality of Life

The ultimate measure of any medical innovation is its impact on human lives. For individuals and families burdened by recurrent RTIs, the cycle of illness, missed school or work, and anxiety is exhausting. As Vildana Mujkić of the Global Allergy & Airways Patient Platform (GAAPP) noted, “For individuals living with recurrent respiratory infections, prevention is not just a clinical objective—it is key to reducing their overall disease burden.”

The REACH study translates complex data into a simple, powerful promise: fewer infections. It provides tangible evidence that a proactive, preventive approach can lead to healthier, more active lives. In showing that Broncho-Vaxom® effectively reduces the need for medical intervention in the real world, OM Pharma is not just selling a product; it is selling the possibility of normalcy to patients who have had their lives disrupted by recurring illness. This patient-centered value proposition is perhaps the most crucial bottom line of all.